Topics

Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver

06:54 EDT 30 Apr 2019 | SCRIP

Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics...

      

Related Stories

 

Original Article: Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver

NEXT ARTICLE

More From BioPortfolio on "Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...